Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Amgen Inc. (AMGN : NSDQ)

• Company Description    Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy. Number of Employees: 28,000

• Price / Volume Information    Yesterday's Closing Price: $319.86 Daily Weekly Monthly 20 Day Moving Average: 2,248,722 shares Shares Outstanding: 538.36 (millions) Market Capitalization: $172,200.42 (millions) Beta: 0.45 52 Week High: $335.88 52 Week Low: $253.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.57% 7.89% 12 Week 10.55% 5.19% Year To Date 22.72% 6.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE AMGEN CENTER DRIVE - THOUSAND OAKS,CA 91320 USA ph: 805-447-1000 fax: 805-447-1010 investor.relations@amgen.com http://www.amgen.com

• General Corporate Information    Officers Robert A. Bradway - Chief Executive Officer; Chairman of the Board and Peter H. Griffith - Executive Vice President and Chief Financial Offic Matthew C. Busch - Vice President; Finance and Chief Accounting Offic Wanda M. Austin - Director Michael V. Drake - Director Peer Information Amgen Inc. (CORR.) Amgen Inc. (RSPI) Amgen Inc. (CGXP) Amgen Inc. (BGEN) Amgen Inc. (GTBP) Amgen Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 031162100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/03/26 Share - Related Items Shares Outstanding: 538.36 Most Recent Split Date: 11.00 (2.00:1) Beta: 0.45 Market Capitalization: $172,200.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.98% Current Fiscal Quarter EPS Consensus Estimate: $5.09 Indicated Annual Dividend: $9.52 Current Fiscal Year EPS Consensus Estimate: $21.18 Payout Ratio: 0.44 Number of Estimates in the Fiscal Year Consensus: 14.00 Change In Payout Ratio: -0.01 Estmated Long-Term EPS Growth Rate: 5.31% Last Dividend Paid: 08/22/2025 - $2.38 Next EPS Report Date: 02/03/26

• Fundamental Ratios P/E Current FY Estimate: 15.10 Trailing 12 Months: 14.63 PEG Ratio: 2.84 Price Ratios Price/Book: 17.90 Price/Cash Flow: 10.53 Price / Sales: 4.79 EPS Growth vs. Year Ago Period: 1.08% vs. Previous Quarter: -6.31% Sales Growth vs. Year Ago Period: 12.40% vs. Previous Quarter: 4.12% ROE 09/30/25 - 162.59 06/30/25 - 174.71 03/31/25 - 176.11 ROA 09/30/25 - 13.18 06/30/25 - 13.12 03/31/25 - 12.39 Current Ratio 09/30/25 - 1.28 06/30/25 - 1.31 03/31/25 - 1.17 Quick Ratio 09/30/25 - - 06/30/25 - 0.98 03/31/25 - 0.88 Operating Margin 09/30/25 - 32.92 06/30/25 - 33.82 03/31/25 - 32.95 Net Margin 09/30/25 - 19.47 06/30/25 - 18.96 03/31/25 - 17.39 Pre-Tax Margin 09/30/25 - 22.92 06/30/25 - 21.26 03/31/25 - 19.49 Book Value 09/30/25 - 17.87 06/30/25 - 13.81 03/31/25 - 11.54 Inventory Turnover 09/30/25 - 1.83 06/30/25 - 1.79 03/31/25 - 1.74 Debt-to-Equity 09/30/25 - 5.45 06/30/25 - 7.24 03/31/25 - 8.70 Debt-to-Capital 09/30/25 - 84.50 06/30/25 - 87.86 03/31/25 - 89.69

Powered by Zacks Investment Research ©